Neil Clark of Destiny Pharma discusses new research programme and progress on lead clinical assets

Neil Clark, CEO of Destiny Pharma #DEST discusses the start of a new XF-73 research programme as a preventive medicine to alleviate suffering from Oral Mucositis in patients receiving cancer treatment by testing its efficacy in the gold-standard model of OM & also provides an update on the progress of their lead clinical assets.

Highlights

The potential utility of XF-73 in this indication is due to the long-recognised association between the development of OM and changes in the oral microbiome. The unique antimicrobial properties of XF‑73 have already been demonstrated in Phase 2 clinical trials. As well as having fast-acting antimicrobial activity and a novel mechanism of action, XF-73 has an excellent safety profile and a lack of systemic exposure which means that it is ideally suited for development as an innovative oral formulation to reduce the severity of OM.

Inflammation of the mucosa (mucositis) is considered one of the most serious non-hematological complications of cancer treatment and a common dose-limiting complication of high-dose radiotherapy and chemotherapy in cancer and bone marrow transplant patients of all ages. Globally, more than two million cancer patients suffer from this condition each year. The global OM market was estimated at $2.2b in 2018.

To read the full RNS click here